Products
Nadroparin is commercially available as a solution for injection (Fraxiparine, Fraxiforte). It has been approved in many countries since 1988.
Structure and properties
Nadroparin is present in the drug as nadroparin calcium. It is the calcium salt of a low-molecular-weight heparin obtained by depolymerization of heparin from the intestinal mucosa of pigs using nitrous acid, most of which is freed from molecules with a molecular weight of less than 2000 Da by fractionation. The product has an average molecular mass of 4300 Da.
Effects
Nadroparin (ATC B01AB06) has antithrombotic properties. The effects are primarily due to inhibition of blood clotting factor Xa by formation of a complex with antithrombin III. Unlike standard heparin, thrombin (factor IIa) is less inhibited, and nadroparin has a longer half-life.
Indications
For prevention and treatment of thromboembolic disease.
Dosage
According to the SmPC. The drug is injected subcutaneously.
Contraindications
For complete precautions, see the drug label.
Interactions
Drug-drug interactions are possible with other antithrombotics, anticoagulants, and NSAIDs. These increase the risk of bleeding.
Adverse effects
The most common potential adverse effects include bleeding and injection site reactions and bruising.
